AU2019328532A1 - Inhibition of RIP kinases for treating neurodegenerative disorders - Google Patents
Inhibition of RIP kinases for treating neurodegenerative disorders Download PDFInfo
- Publication number
- AU2019328532A1 AU2019328532A1 AU2019328532A AU2019328532A AU2019328532A1 AU 2019328532 A1 AU2019328532 A1 AU 2019328532A1 AU 2019328532 A AU2019328532 A AU 2019328532A AU 2019328532 A AU2019328532 A AU 2019328532A AU 2019328532 A1 AU2019328532 A1 AU 2019328532A1
- Authority
- AU
- Australia
- Prior art keywords
- ripk2
- disease
- inhibitor
- microglia
- nod2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Psychology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862725647P | 2018-08-31 | 2018-08-31 | |
US62/725,647 | 2018-08-31 | ||
PCT/US2019/049071 WO2020047414A1 (en) | 2018-08-31 | 2019-08-30 | Inhibition of rip kinases for treating neurodegenerative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2019328532A1 true AU2019328532A1 (en) | 2021-03-11 |
Family
ID=69643080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2019328532A Abandoned AU2019328532A1 (en) | 2018-08-31 | 2019-08-30 | Inhibition of RIP kinases for treating neurodegenerative disorders |
Country Status (8)
Country | Link |
---|---|
US (1) | US20210322427A1 (zh) |
EP (1) | EP3843773A4 (zh) |
JP (1) | JP2021535152A (zh) |
KR (1) | KR20210053303A (zh) |
CN (1) | CN112638405A (zh) |
AU (1) | AU2019328532A1 (zh) |
CA (1) | CA3109364A1 (zh) |
WO (1) | WO2020047414A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023055733A1 (en) * | 2021-09-30 | 2023-04-06 | The Scripps Research Institute | Compounds for reducing neuroinflammation |
WO2023229445A1 (ko) * | 2022-05-27 | 2023-11-30 | 주식회사 진큐어 | 신규 펩타이드 및 그의 용도 |
WO2024099363A1 (zh) * | 2022-11-09 | 2024-05-16 | 宁波康柏睿格医药科技有限公司 | Rip2抑制剂联合免疫检查点抑制剂药物组合物及其应用 |
CN116617224A (zh) * | 2023-05-04 | 2023-08-22 | 上海交通大学医学院附属瑞金医院 | OPN和p38 MAPK信号通路靶向调控剂在制备神经退行性疾病药物中的应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130005726A1 (en) * | 2010-03-08 | 2013-01-03 | Derek Abbott | Compositions and methods for treating inflammatory disorders |
US20120046329A1 (en) * | 2010-08-10 | 2012-02-23 | Sanford-Burnham Medical Research Institute | Modulators of nod1 and nod2 signaling, methods of identifying modulators of nod1 and nod2 signaling, and uses thereof |
US9408873B2 (en) * | 2010-08-23 | 2016-08-09 | Kang Stem Biotech Co., Ltd. | Pharmaceutical composition comprising stem cells treated with NOD2 agonist or culture thereof for prevention and treatment of immune disorders and inflammatory diseases |
SI2729173T1 (sl) * | 2011-07-06 | 2016-10-28 | Sykehuset Sorlandet Hf | Terapija, ki cilja na EGFR |
US20150292012A1 (en) * | 2012-10-26 | 2015-10-15 | Case Western Reserve University | Biomarkers for nod2 and/or rip2 activity related application |
US20170003280A1 (en) * | 2014-01-11 | 2017-01-05 | The J. David Gladstone Institutes | In vitro assays for inhibition of microglial activation |
WO2016096709A1 (en) * | 2014-12-16 | 2016-06-23 | Eudendron S.R.L. | Heterocyclic derivatives modulating activity of certain protein kinases |
KR20160129609A (ko) * | 2015-04-30 | 2016-11-09 | 삼성전자주식회사 | Braf 저해제를 포함하는 세포 또는 개체의 노화를 감소시키기 위한 조성물 및 그의 용도 |
-
2019
- 2019-08-30 WO PCT/US2019/049071 patent/WO2020047414A1/en unknown
- 2019-08-30 CA CA3109364A patent/CA3109364A1/en active Pending
- 2019-08-30 JP JP2021510846A patent/JP2021535152A/ja active Pending
- 2019-08-30 EP EP19853529.6A patent/EP3843773A4/en active Pending
- 2019-08-30 AU AU2019328532A patent/AU2019328532A1/en not_active Abandoned
- 2019-08-30 KR KR1020217008526A patent/KR20210053303A/ko active Search and Examination
- 2019-08-30 CN CN201980057467.0A patent/CN112638405A/zh active Pending
- 2019-08-30 US US17/271,966 patent/US20210322427A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3843773A4 (en) | 2022-06-08 |
CA3109364A1 (en) | 2020-03-05 |
CN112638405A (zh) | 2021-04-09 |
US20210322427A1 (en) | 2021-10-21 |
JP2021535152A (ja) | 2021-12-16 |
WO2020047414A1 (en) | 2020-03-05 |
KR20210053303A (ko) | 2021-05-11 |
EP3843773A1 (en) | 2021-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210322427A1 (en) | Inhibition of rip kinases for treating neurodegenerative disorders | |
Dobolyi et al. | The neuroprotective functions of transforming growth factor beta proteins | |
Yu et al. | MSX3 switches microglia polarization and protects from inflammation-induced demyelination | |
US20210222164A1 (en) | Crispr-cas systems having destabilization domain | |
Jana et al. | Human immunodeficiency virus type 1 gp120 induces apoptosis in human primary neurons through redox-regulated activation of neutral sphingomyelinase | |
JP6755938B2 (ja) | アルツハイマー病の治療におけるPI4KIIIαタンパク質および関連膜タンパク質複合体の利用 | |
Zhong et al. | Lipid transporter Spns2 promotes microglia pro‐inflammatory activation in response to amyloid‐beta peptide | |
US20230414658A1 (en) | Methods of treating or preventing alzheimer's disease and associated conditions | |
Yao et al. | Genetic imaging of neuroinflammation in Parkinson’s disease: Recent advancements | |
Gagliardi et al. | Micro RNA s as regulators of cell death mechanisms in amyotrophic lateral sclerosis | |
PT1456380E (pt) | Inibidores smad7 para o tratamento de doenças do snc | |
US20190216891A1 (en) | Method for modulating myelination | |
US20160208267A1 (en) | Antisense Oligonucleotides Against Neutral Sphingomyelinase and Neutral Sphingomyelinase Inhibitor GW4869 for Degenerative Neurological Disorders | |
US8343938B2 (en) | Uses and compositions comprising miRNAs | |
Guan et al. | Molecular mechanism of acetylsalicylic acid in improving learning and memory impairment in APP/PS1 transgenic mice by inhibiting the abnormal cell cycle re-entry of neurons | |
EP3016661B1 (fr) | Inhibition de la synthèse de la protéine beta-app ou de l'activité du peptide a-beta dans les plexus choroïdes | |
JP2024513003A (ja) | Csf1rアンタゴニストに対する耐性を付与するための哺乳動物細胞の遺伝子改変 | |
WO2018237383A1 (en) | METHODS OF PREVENTING AND TREATING DISEASES CHARACTERIZED BY SYNAPTIC DYSFUNCTION AND NEURODEGENERATION, INCLUDING ALZHEIMER'S DISEASE | |
TWI601821B (zh) | 治療神經發展性疾病 | |
US9675590B2 (en) | Methods and pharmaceutical compositions for the treatment of myelodysplastic syndromes | |
deSouza et al. | Etiology and pathogenesis of Parkinson disease | |
US20230374509A1 (en) | Microrna inhibitor system and methods of use thereof | |
KR20180112649A (ko) | 신경 퇴행성 뇌질환 예방 또는 치료용 약학 조성물 및 이의 스크리닝 방법 | |
JP7062292B2 (ja) | リン脂質ヒドロペルオキシド依存性細胞死の抑制剤及びリン脂質ヒドロペルオキシド依存性細胞死が関連する疾患の予防又は治療剤 | |
JP2020517580A (ja) | 電離放射線耐性腫瘍を治療するための方法及び組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |